EFFECT OF THE COMBINATION OF LERCANIDIPINE AND CARVEDILOL ON THE FUNCTIONAL STATE OF THE HEART IN PATIENTS WITH CHRONIC HEART FAILURE AND ARTERIAL HYPERTENSION

Authors:

Abstract:

To study the effect of a combination of lercanidipine and carvedilol on heart failure, 36 patients with arterial hypertension and I–III functional state heart failure according to the New York Heart Association classification were enrolled in the study (Group A). The control group consisted of 32 patients with the same pathology (Group B). The groups were divided into subgroups (3 per group) according to the functional states I, II, and III. Subgroups from Group A received lercanidipine and carvedilol, while subgroups from Group B received only carvedilol for 6 months. After treatment, significant improvements in systolic and diastolic function parameters were observed in all subgroups from Group A (p<0.05). The magnitude of improvement was most significant in patients with functional class I and progressively attenuated in functional classes II and III. In all subgroups of Group B, only early diastolic filling deceleration time and left ventricular isovolumetric relaxation time improved reliably (p<0.05).

Keywords:

arterial hypertension left ventricular hypertrophy. carvedilol lercanidipine chronic heart failure

References:

1. Agostoni P, Chiesa M, Salvioni E, Emdin M, Piepoli M, Sinagra G, et al; MECKI score research group. The chronic heart failure evolutions: Different fates and routes. ESC Heart Fail. 2025 Feb;12(1):418-433. doi: 10.1002/ehf2.14966.
2. Blanch P, Freixa-Pamias R. Diagnosis and management of diastolic dysfunction in arterial hypertension. Hipertens Riesgo Vasc. 2025 Jul-Sep;42(3):237-246. doi: 10.1016/j.hipert.2025.06.002.
3. Derosa G, Mugellini A, Querci F, Franzetti I, Pesce RM, D'Angelo A, et al. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. Sci Rep. 2015 Aug 5;5:12603. doi: 10.1038/srep12603.
4. Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K, et al. Beta-Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy. J Am Heart Assoc. 2021 Jun 15;10(12):e019240. doi: 10.1161/JAHA.120.019240.
5. Falcão-Pires I, Ferreira AF, Trindade F, Bertrand L, Ciccarelli M, Visco V, et al. Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function. Eur J Heart Fail. 2024 Jul;26(7):1454-1479. doi: 10.1002/ejhf.3264.
6. Fici F, Seravalle G, Koylan N, Nalbantgil I, Cagla N, Korkut Y, et al. Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. High Blood Press Cardiovasc Prev. 2017 Sep;24(3):289-296. doi: 10.1007/s40292-017-0208-1.
7. Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. 2017 Oct-Dec;8(4):155-165. doi: 10.4103/jpp.JPP_34_17.
8. Jeon J, Ryoo S, Oh S, Jun HS, Cheol WY, Hyun KY, et al. Comparative Effectiveness of Lercanidipine and Amlodipine on Major Adverse Cardiovascular Events in Hypertensive Patients, American Journal of Hypertension, Volume 38, Issue 2, February 2025, Pages 139–147, https://doi.org/10.1093/ajh/hpae147.
9. Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nat Rev Cardiol. 2024 Oct;21(10):717-734. doi: 10.1038/s41569-024-01046-6.
10. Kuchynka P, Podzimkova J, Marek J, Danek BA, Vitkova I, Kreidlova M, et al. Long-term outcomes and reverse remodelling in recently diagnosed unexplained left ventricular systolic dysfunction. ESC Heart Fail. 2024 Apr;11(2):859-870. doi: 10.1002/ehf2.14643.
11. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670.
12. Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2023 Jun;25(6):776-791. doi: 10.1002/ejhf.2874.
13. Ottosen CI, Nadruz W, Inciardi RM, Johansen ND, Fudim M, Biering-Sørensen T. Diastolic dysfunction in hypertension: a comprehensive review of pathophysiology, diagnosis, and treatment. Eur Heart J Cardiovasc Imaging. 2024 Oct 30;25(11):1525-1536. doi: 10.1093/ehjci/jeae178.
14. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther 2021;11(1):263-276.
15. Shams P, Malik A, Chhabra L. Heart Failure (Congestive Heart Failure) [Updated 2025 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430873/

Publication:

«World of Medicine and Biology» Vol. 21 No. 94 (2025) , с. 77-82
УДК 616.12-008.46-085.22

DOI:

https://doi.org/10.26724/2079-8334-2025-4-94-77-82